Polycomb repressive complex 2 (PRC2) catalyzes the monomethylation, dimethylation, and trimethylation of histone H3 Lys27 (H3K27) and acts as a central epigenetic regulator that marks the repressive chromatin domain. Embryonic ectoderm development (EED), an essential component of PRC2, interacts with trimethylated H3K27 (H3K27me3) through the aromatic cage structure composed of its three aromatic amino acids, Phe97, Trp364, and Tyr365. This interaction allosterically activates the histone methyltransferase activity of PRC2 and thereby propagates repressive histone marks. In this study, we report the analysis of knock-in mice harboring the myeloid disorder-associated EED Ile363Met (I363M) mutation, analogous to the EED aromatic cage mutants. The I363M homozygotes displayed a remarkable and preferential reduction of H3K27me3 and died at midgestation. The heterozygotes increased the clonogenic capacity and bone marrow repopulating activity of hematopoietic stem/progenitor cells (HSPCs) and were susceptible to leukemia. Lgals3, a PRC2 target gene encoding a multifunctional galactose-binding lectin, was derepressed in I363M heterozygotes, which enhanced the stemness of HSPCs. Thus, our work provides in vivo evidence that the structural integrity of EED to H3K27me3 propagation is critical, especially for embryonic development and hematopoietic homeostasis, and that its perturbation increases the predisposition to hematologic malignancies.
Polycomb repressive complex 2 (PRC2) catalyzes the monomethylation, dimethylation, and trimethylation of histone H3 Lys27 (H3K27) and acts as a central epigenetic regulator that marks the repressive chromatin domain. Embryonic ectoderm development (EED), an essential component of PRC2, interacts with trimethylated H3K27 (H3K27me3) through the aromatic cage structure composed of its three aromatic amino acids, Phe97, Trp364, and Tyr365. This interaction allosterically activates the histone methyltransferase activity of PRC2 and thereby propagates repressive histone marks. In this study, we report the analysis of knock-in mice harboring the myeloid disorder-associated EED Ile363Met (I363M) mutation, analogous to the EED aromatic cage mutants. The I363M homozygotes displayed a remarkable and preferential reduction of H3K27me3 and died at midgestation. The heterozygotes increased the clonogenic capacity and bone marrow repopulating activity of hematopoietic stem/progenitor cells (HSPCs) and were susceptible to leukemia. Lgals3, a PRC2 target gene encoding a multifunctional galactose-binding lectin, was derepressed in I363M heterozygotes, which enhanced the stemness of HSPCs. Thus, our work provides in vivo evidence that the structural integrity of EED to H3K27me3 propagation is critical, especially for embryonic development and hematopoietic homeostasis, and that its perturbation increases the predisposition to hematologic malignancies.
histone methylation | repressive histone marks | hematologic malignancies P olycomb repressive complex 2 (PRC2) catalyzes the monomethylation, dimethylation, and trimethylation of histone H3 Lys27 (H3K27) and plays a critical role in the epigenetic maintenance of repressive chromatin states. Histone-lysine N-methyltransferase EZH2 is inactive on its own, even though the histone-lysine methyltransferase activity of PRC2 resides in the SET domain of EZH2 (1) . EZH2 is required to interact with other noncatalytic proteins, including the WD repeat-containing polycomb protein embryonic ectoderm development (EED) and the zinc finger protein SUZ12, to fully exert histone methyltransferase activity (1) . In mice, homozygotes for Eed null mutations show abolished global H3K27 monomethylation, dimethylation, and trimethylation, resulting in lethality by embryonic day (E) 9.5 owing to a defect in primitive streak formation (2, 3) . Along with its action in PRC2 complex formation, the EED-H3K27me3 interaction allosterically activates the enzymatic activity of PRC2 before propagating H3K27me3-repressive histone marks in a positive feedback loop (4) . Phe-97, Trp-364, and Tyr-365 in human EED are required to form the so-called "aromatic cage" structures that can recognize H3K27me3 histone marks (4) .
Accumulating evidence implicates a genetic loss of PRC2 function in patients with hematologic malignancies. Deletions and missense/nonsense mutations of PRC2 components have been shown in myelodysplastic syndrome and myeloproliferative disorders, as well as in T-cell leukemia, and mostly predict inactivation of PRC2 function (5) . We previously identified the EED gene mutations impairing PRC2 function in 3.1% of human myeloid disorders (6) . Among these mutants, the Ile-to-Met mutation at amino acid 363 (I363M) of EED, which is located adjacent to the residues constituting the aromatic cage structure, has been shown to have impaired binding ability to an H3K27me3 peptide, where it should interact with EZH2. Overexpression of the I363M-mutated protein led to a decrease of global H3K27me3 levels in mouse fibroblast cell line NIH 3T3, indicating that this mutant attenuated the propagation of repressive histone marks through impaired integrity of the aromatic cage structure (6) .
Increased susceptibility to hematologic tumors was previously reported with Eed heterozygotes and homozygous hypomorphs (7) (8) (9) . These Eed mutations blocked the interaction between EED and EZH2 and/or destabilized the mutated EED proteins (3, 10, 11) , which are considered to compromise the overall PRC2 complex Significance Polycomb repressive complex 2 (PRC2) is a central regulator in all forms of histone H3 Lys27 (H3K27) methylation. Interaction of embryonic ectoderm development (EED) with trimethylated H3K27 (H3K27me3) is required for the allosteric activation of PRC2. We previously identified a myeloid disorder-associated EED Ile363Met (I363M) mutation with impaired binding ability to H3K27me3. By generating I363M knock-in mice, we demonstrated that I363M preferentially dampened the propagation of H3K27me3 repressive marks in vivo. The homozygotes caused embryonic lethality, whereas the heterozygotes enhanced hematopoietic stem/progenitor cell (HSPC) activity, coupled with susceptibility to leukemia. Lgals3, a PRC2 target gene, was derepressed by I363M, which enhanced the stemness of HSPCs. Our findings highlight the significance of the structural integrity of EED in cellular homeostasis and tumor suppression.
formation and the enzymatic activity involving H3K27 monomethylated, dimethylated, and trimethylated forms.
In this study, to investigate the in vivo effect of the I363M mutation on disease pathogenesis, we generated and analyzed knock-in (KI) mice with the I363M mutant of EED (EED I363M). We demonstrate that unlike EED deficiency, which abrogates H3K27me1, H3K27me2, and H3K27me3, the I363M mutant preferentially dampens the propagation of H3K27me3-repressive histone marks. This finding allows us to consider that mice carrying I363M might be an excellent model for analyzing H3K27me3-preferential roles in vivo. We report the results of our phenotypic, molecular, biochemical, and hematologic analyses of the mutant.
Results and Discussion
Forced Expression of EED I363M or Aromatic Cage Mutants Decreases H3K27me3 Levels in K562 Cells. To compare the impact of I363M on the levels of H3K27me3 with the aromatic residue-mutated EED proteins, we first established human chronic myeloid leukemia K562 cells expressing wild-type (WT) EED [441 amino acids, NP_003788.2 (human)], I363M, and two aromatic cage mutants, Phe97Ala (F97A) and Trp364Ala (W364A) (Fig. 1A) . We found that I363M, but not WT, EED led to a reduction in global H3K27me3 levels, as expected; in addition, forced expression of the two aromatic cage mutants also displayed more profoundly decreased global H3K27me3 levels (Fig. 1B) .
We examined the mRNA levels of ITLN2, SLC4A1, and KLHDC8A, which contain gene regions marked by H3K27me3 and EZH2 in K562 cells, according to ENCODE chromatin immunoprecipitation (ChIP)-sequencing datasets (Fig. S1 ). Among these, the ITLN2 gene was up-regulated in cells expressing the mutated EED proteins compared with those expressing WT EED, although the expression of KLHDC8A and SLC4A1 was unaffected (Fig. 1C) . The ITLN2 gene derepression was apparently correlated with the effect of EED mutants on H3K27me3 levels. Thus, I363M acted as an antimorphic mutant of EED, analogous to the aromatic cage mutants. Fig. 2A and Fig. S3A ). The live embryos at E12.5-E13.5 were not anemic, and had normal-sized placentas (Fig. 2B ). There were no apparent structural defects of the tissues, including the lung, heart, and fetal liver, that could account for the lethality on H&E-stained sections of E13.5 live homozygotes (Fig. S3B ). Of note, at E12.5-13.5, the combined number of Eed KI/KI live embryos and absorbed remnants was almost consistent with the Mendelian ratio (Fig. S3A) . Some of the absorbed embryos proved to be homozygotes on genotyping PCR, suggesting postimplantation embryonic lethality of Eed KI/KI mutants. We noted that the size of Eed KI/KI fetal liver was apparently smaller, coupled with significantly reduced cell numbers, although surface markers of blood cells among homozygotes and the corresponding controls were unchanged ( Fig. S3 C and D) . Thus, we performed reconstitution of peripheral blood cells by fetal liver cell transplantation and found that the Eed KI/KI fetal liver cells had a hematopoietic repopulation capacity comparable to that of the Eed +/+ controls (Fig. S3E ). These results suggest that the reduced number of Eed KI/KI fetal liver cells is attributed mostly to a cell-extrinsic mechanism, which is supported by a previous study indicating that homozygous deletion of Eed in the hematopoietic organs caused no critical defects in the fetal liver earlier in midgestation (12 , and Eed KI/KI at similar levels in mouse embryonic fibroblasts (MEFs) from embryos of these three genotypes (Fig.  2C) . WT EED and I363M equivalently interacted with EZH2 and SUZ12, as demonstrated by immunoprecipitation using the anti-EZH2 antibody (Fig. 2D) MEFs, whereas there were no alterations in global H3K27me1/me2 and H3K4me3 levels among these genotypes (Fig. 2E) . Furthermore, Eed KI/+ MEFs also showed lower H3K27me3 levels compared with Eed +/+ MEFs, in agreement with a dominant-negative effect of I363M (Fig. 2E) . These results were validated by immunofluorescent staining (Fig. 2F) . Although marked reduction of H3K27me3 levels was confirmed in Eed KI/KI MEFs by flow cytometry, the fluorescence levels of H3K27me3 in Eed KI/KI cells were higher than those of the fluorescence-conjugated isotype control IgG (Fig. S4A) , suggesting that I363M preferentially but incompletely abrogated the trimethylation form of H3K27.
ChIP sequencing (ChIP-seq) revealed that the average H3K27me3 levels across a genomic window of ±2 kb centered to the H3K27me3 peak summit were profoundly reduced in Eed KI/KI MEFs compared with those in Eed +/+ control cells (Fig. 2G) . Thus, the integrity of the aromatic cage structure was shown to be critical for the propagation of H3K27me3-repressive histone marks as proposed previously (4) . In line with this result, Eed KI/KI cells demonstrated a more precipitous decrease in H3K27me3 levels at regions especially distal from transcription start site (TSS) ±1kb compared with the Eed +/+ controls, whereas a comparable strong peak enrichment with a sharp dip was detected within TSS ±1kb in these two genotypes (Fig. 2H) .
We further investigated the effect of I363M on the distributions of H3K27me1 and K27me2 by ChIP-seq. The H3K27me1 and K27me2 occupancy around TSS was slightly altered by I363M, whereas the entire pattern of the cistromes was comparable in Eed +/+ and Eed KI/KI MEFs (Fig. 2I ). These epigenetic alterations also might influence the gene expression in part, although at this point we are unable to address whether the altered H3K27me1 and K27me2 arise from a direct effect of the I363M mutation or from a secondary process caused by the decreased amount of H3K27me3.
The Eed KI/KI mutants displayed embryonic lethality at a broader spectrum of developmental stages than the Eed null homozygous embryos (2), possibly highlighting the developmentally preferential role of H3K27me3 distinct from H3K27 monomethylation and dimethylation. (Fig. S4B) . We detected lower levels of H3K27me3 in Eed KI/+ LSK cells, as expected (Fig. S4C) .
The total BM cell numbers were normal in young Eed KI/+ mice (6-12 wk), but increased in older mutants after a 1.5-y follow-up (Fig. 3B) . Furthermore, BM hematopoietic progenitors, defined as a 
, and megakaryocyte-erythroid progenitors, underwent a significant age-dependent expansion in the Eed KI/+ BM ( Fig. 3C and Fig. S5A ), although there were no alterations in the LSK population between these time points (Fig. S5B) . Aged Eed KI/+ mice (not young) exhibited a significant increase in white blood cell counts, including myeloid cell, B-cell, and T-cell lineages, in the peripheral blood compared with the Eed +/+ mice ( Fig. 3D and Fig. S5C ). The Eed KI/+ mice also displayed splenic hypercellularity at a younger age (Fig. S5D) . Although splenomegaly was observed in some older Eed KI/+ mice at around 1.5 y of age, there was no obvious lineage bias in these enlarged spleens (Fig. S5 E and F) . Thus, the I363M mutation resulted in leukocytosis and an age-dependent hypercellularity in the hematopoietic tissues, whereas I363M alone was considered insufficient for hematopoietic transformation in mice.
To evaluate the effect of I363M on the clonogenic potential of hematopoietic cells, we subjected c-Kit + HSC/progenitor cells from BM to serial hematopoietic granulocyte-macrophage colonyforming (CFU-GM) assays. On the first and second plating rounds, there was no difference in the number of colonies between the Eed +/+ and Eed KI/+ cells; however, Eed KI/+ cells exhibited continuous growth and generated significantly more concentric colonies after the third plating, whereas the colony-replating capacity of Eed +/+ cells was substantially reduced (Fig. 3 E and F) . The replated Eed KI/+ colonies were homogeneous and less differentiated, containing myeloblast-like cells (Fig. 3G) + cell numbers in the peripheral blood (Fig. 3I) . Thus, Eed KI/+ BM HSCs were shown to have a cell-autonomous growth advantage. Our results are similar to those of previous studies reporting that the heterozygous null mutation of Eed confer a growth advantage for BM HSCs (7, 12) , whereas homozygous deletion of Eed in the hematopoietic cells results in severe HSC exhaustion only in the BM after birth (12) . Therefore, complete loss of function and impaired function of EED appear to have different (possibly opposing) effects on BM hematopoiesis.
The Eed Mutation Primed Comprehensive Gene Alterations That
Deregulated Hematopoietic Homeostasis. To determine the molecular basis of the increased hematopoietic activity by the I363M mutation, we performed RNA sequencing of LSK cells, followed by Gene Set Enrichment Analysis (GSEA) for genes involved in hematopoiesis and Gene Ontology (GO) biological process category. Eed KI/+ LSK cells showed significant enrichment of primitive HSC-specific genes harboring bivalent histone modifications, activating H3K4me3, and repressive H3K27me3 associated with stem cell maintenance (Fig. 4A, Left) (15) . Furthermore, I363M induced a significant enrichment of genes involving cellular signaling and homeostasis, as represented by cyclic nucleotide-mediated signaling, G protein coupled to nucleotide signaling, and cellular cation homeostasis (Fig. 4A , Middle and Table S1 ). In Eed KI/+ LSKs, the granulocyte fingerprint (16) was up-regulated and genes involved in immune regulation (lymphoid) were down-regulated, which potentially contributed to a more statistically significant shift of myeloid lineage in the peripheral blood and thereby enhanced CFU-GM capacity (Fig. 4A, Right and Table S1 ).
To focus on the differentially expressed genes associated with deregulated PRC2 function, we used the reported gene expression data from mice harboring the Suz12 Plt8 mutation. Mice heterozygous for the Suz12 Plt8 allele (Suz12 Plt8/+ mice) were reported to show leukocytosis and enhanced HSC repopulating activity, whereas homozygotes showed embryonic lethality, resembling the phenotypes of Eed I363M mutants (17, 18) . By direct comparison of genes upregulated in LSK cells, we identified 19 up-regulated genes potentially associated with PRC2 deregulation in both mutants (Fig. S6A ). Among these, Lgals3, encoding Galectin-3, was identified as the most up-regulated gene in Eed KI/+ and Suz12 Plt8/+ cells, which is marked by H3K27me3 at TSS ±1kb according to the reported ChIPseq for LSK (19) (Fig. 4B and Fig. S6A ). Galectin-3 is a multifunctional β-galactose-binding lectin reported to be involved in various biological processes, including cell growth and differentiation (20) . ChIP experiments followed by PCR (ChIP-PCR), using an anti-H3K27me3 antibody, demonstrated significantly lower H3K27me3 levels on the promoter region of the Lgals3 gene in Eed KI/+ cells compared with controls ( Fig. 4C and Fig. S6B ), indicating derepression of Lgals3 by the I363M mutation. Transient knockdown of Lgals3 in Eed KI/+ c-Kit + cells led to impaired colony-formation capability at the successive platings, thereby suppressing the long-term stemness rather than clonogenicity itself (Fig. 4D and Fig. S6C) . Furthermore, when retrovirally transduced with Lgals3-IRES-EGFP (i.e., internal ribosome entry site-enhanced green fluorescent protein cassette), the WT c-Kit + BM cells retained a higher population of immature cells with blast-like morphology, in correlation with the expression level of EGFP after serial replatings (Fig. 4 E and F and Fig. S6D ). In line with this observation, concentric colony formation was sustained for longer periods by Lgals3 overexpression, whereas the numbers of Lgals3-transduced colonies and vector controls apparently decreased in a comparable manner (Fig. 4G and  Fig. S6E ). These results indicate that derepression of Lgals3, a PRC2 target gene, contributes to the stemness of HSPCs. Human chronic myeloid leukemia cells overexpressing LGALS3 showed increased proliferation and cell accumulation in the BM in a xenograft model (21) . Clinically, higher expression of LGALS3 is considered a poor prognostic factor for overall survival in patients with acute myeloid leukemia (22) . Thus, deregulated expression of Lgals3 may contribute to tumor susceptibility, malignant transformation, and leukemia development.
The I363M Mutation Increases Susceptibility to Leukemia and Causes
Myeloid Leukemia with Overexpressed Evi1. Eed KI/+ mice survived as long as Eed +/+ controls over 1.5 y. Because the I363M mutation was originally identified in human myeloid disorders, we investigated whether the I363M mutation influences the susceptibility to hematologic malignancies by retroviral insertional mutagenesis. To do so, we infected Eed KI/+ and Eed +/+ neonates with a replication-competent Moloney murine leukemia retrovirusbased MOL4070LTR with the ability to induce malignant myeloid disorders and lymphoid leukemias (23) . This protocol profoundly accelerated disease onset and mortality in the Eed KI/+ neonates (Fig. 5A) , and myeloid or T-cell malignancies were observed, corresponding to the clinical phenotypes of patients with loss-of-function mutations in the PRC2-associated genes (5) ( Table S2 ). More specifically, 5 of 14 virus-infected Eed KI/+ mice developed myeloid diseases involving distinct differentiation stages, as determined by Wright-Giemsa staining (Fig. 5B , Left and Middle) and analysis of surface markers (increased Mac1
+

Gr1
− and Mac1 + Gr1 + populations) (Fig. 5B , Right and Table S2 ). Thus, EED I363M predisposes mice to malignancy, including myeloid disorders, synergistically with additional gene alterations.
To identify genes cooperating with the I363M mutation in mice, we extracted genomic DNA from the leukemic tissue of the virus-infected mice and subjected it to inverse PCR to detect virus integration sites (24) . We identified five genes representing common integration sites in Eed KI+ tumor samples, and then used quantitative PCR to verify that two genes, Evi1 and Runx2, were highly expressed in the corresponding tumor tissues (Fig. 5C and Table S2 ). In fact, Evi1 was strikingly up-regulated in four of the five myeloid tumors ( Fig. 5C ; mice 3, 6, 8, and 12 in Table S2 ), whereas Runx2 was elevated in three of the eight T-cell leukemia samples ( Fig. 5C ; mice 1, 13, and 14 in Table S2 ). This result supported Eed I363M genetically cooperates with Evi1 and Runx2 toward myeloid diseases and T-cell leukemia, respectively.
EVI1, which encodes a zinc finger-containing DNA-binding protein, has been reported to be highly expressed in myelodysplastic syndromes and myeloid leukemia (25) . We accordingly inspected the gene expression levels of EVI1 and PRC2 core components in 179 cases of acute myeloid leukemia (AML) from The Cancer Genome Atlas (TCGA) database, based on data availability (26) . We found that EVI1 was elevated in 17 cases of AML at extremely high levels (>100-fold of the median reads per kb per million) (Fig. 5D, Upper) ; however, because all cases of AML had comparable EED and SUZ12 expression levels, we could not detect a substantial correlation in gene expression between EVI1 and these genes. Nevertheless, the AML cases that highly expressed EVI1 correlated significantly with lower levels of EZH2 gene expression (Fig. 5D, Lower) . These data suggest a synergistic role of EVI1 activation and impaired PRC2 function in myeloid diseases.
Tumor susceptibility caused by the aromatic cage mutation may be reminiscent of the histone H3 Lys27Met mutations identified in patients with gliomas. These histone mutations halt PRC2 complex formation by increasing the affinity to EZH2, resulting in an arrest of H3K27me3 propagation (27) . Thus, impaired H3K27me3 propagation might be a crucial step in promoting solid tumors, not only hematologic neoplasms.
In conclusion, in this study we have highlighted the biological importance of the structural integrity of EED to H3K27me3 propagation, especially for embryonic development and hematopoietic homeostasis, and demonstrated that this disruption predisposes mice to hematologic malignancies (Fig. S7) . Questions remain concerning tissue-and cell type-specificity and context-dependency of EED function, however, because despite lower levels of H3K27me3, the Eed KI/+ mice were able to survive as long as the Eed +/+ mice. Interestingly, a recent study reported that H3K27me3 propagation is regulated by the JARID2 protein, a cofactor of PRC2 (28) . Future studies are needed to clarify the perplexing and multifaceted in vivo function of PRC2. 
Materials and Methods
The experiment was approved by the Committee on the Ethics of Animal Experiments of the Hiroshima University, and all mice were maintained according to the guidelines of the Institute of Laboratory Animal Science, Hiroshima University.
Cell Culture and Transfection. The K562 cells were transfected with episomal type pEBmulti-Neo-vector (Wako Pure Chemicals) and pEBmulti-Neo-myc-WT EED/myc-F97A/myc-I363M/myc-F364A, using Nucleofection (Amaxa), and then selected by growth in G418 (1 mg/mL) for 7 d.
Nuclear Complex Coimmunoprecipitation. Nuclear protein extraction and coimmunoprecipitation assays were performed using the Nuclear Complex Co-IP Kit (Active Motif), according to the manufacturer's protocol. Nuclear extract (500 μg) was incubated with either mouse IgG or anti-EZH2 antibody (AC22; Millipore), and Dynabeads M-280 sheep anti-mouse IgG (11201D; Life Technologies).
Acid Extraction of Histones. Cells were lysed in Triton extraction buffer [0.5% (vol/vol) of Triton-X100 and protease inhibitor mixture (Roche) in PBS] for 10 min on ice. The pellet was washed in Triton extraction buffer and then resuspended in 0.2 M HCl for acid extraction overnight at 4°C. The supernatants were subjected to immunoblotting.
Immunoblotting. The following antibodies were used for immunoblotting: anti-EED (05-1320 or 17-10034), anti-EZH2 (05-1319), and anti-monomethylhistone H3 (Lys27) (07-448) (Millipore); anti-c-Myc (sc-40) and anti-SUZ12 (sc-46264) (Santa Cruz Biotechnology); anti-trimethyl-histone H3 (Lys27) (9733) (Cell Signaling Technology) and anti-histone H3 (3638; Cell Signaling Technology or 05-499; Millipore); anti-di-methyl-histone H3 (Lys27) (ab24684) and anti-trimethyl-histone H3 (Lys4) (ab8550) (Abcam); antiLgals3 (12733) (Cell Signaling Technology); and anti-β-actin (Sigma-Aldrich). Standard lysate preparation and electroblotting protocols were followed unless stated otherwise.
Retroviral Gene Transduction. c-Kit + BM cells were cultured in medium containing 100 ng/mL SCF, 100 ng/mL TPO, and 20 ng/mL IL-6. Cells were infected twice with a retrovirus vector, with a 24-h interval between infections. Sorted EGFP + cells were used for subsequent experiments.
Immunofluorescence. For immunostaining, standard protocols were applied, using trimethyl-histone H3 (Lys27) rabbit monoclonal antibody (9733; Cell Signaling Technology) and Alexa Fluor 488-conjugated anti-rabbit IgG antibody (Invitrogen). The nuclei were counterstained with Hoechst 33342.
Colony-Forming Assay. Cells were plated in MethoCult GF M3534 (STEMCELL Technologies). Colony numbers were counted, and cells were collected, pooled, and replated at the indicated cell numbers per 35-mm plate.
Competitive BM Reconstitution Assay. Dose of 2 × 10 3 LSK cells from 10-wk-old Eed KI/+ and Eed +/+ mice (Ly5.2 + ) were administered i.v. into 8-wk-old C57BL/ 6-Ly5.1 mice irradiated with a dose of 8.5 Gy together with 2 × 10 5 BM competitor cells from C57BL/6-Ly5.1 mice.
Electroporation of siRNAs into Hematopoietic Cells. Here 1 × 10 6 c-Kit + BM cells were cultured in X-VIVO15 (Lonza) supplemented with cytokines (SCF, 100 ng/mL; TPO, 100 ng/mL; IL-6, 20 ng/mL) and then nucleofected using the Amaxa Mouse Macrophage Nucleofector Kit (program Y-001) and 100 pmol mouse Lgals3 pooled siRNA (ON-TARGETplus) or siCONTROL Non-Targeting Pool (Dharmacon). At 24 h after nucleofection, the cells were plated for the CFU-GM assay.
MOL4070LTR Retrovirus Injection. Preparation and infection of retrovirus were performed as described by Wolff et al. (23) . Newborn pups from the breeding mice were inoculated i.p. with virus solution. Identification of retroviral integration sites was performed as described previously (29) .
Statistics. Mouse survival curves were constructed using Kaplan-Meier methodology and compared by the log-rank test using GraphPad Prism software. Unless stated otherwise, other statistical analyses were performed using Student's t test.
